| Name | Title | Contact Details |
|---|
Help control your eye pressure and possibly reduce your need for Glaucoma medication with the Hydrus® Microstent.
Qualitest Pharmaceuticals is a Charlotte, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The new and innovated concept of DeliverIt Pharmacy came from our 20 years of experience. We have seen it all, the frustrations and hassles customers have to go through just to get their prescription. At DeliverIt Pharmacy we strive to keep the balance of affordable and convenience for our customers while performing proficiently and efficiently. We conveniently offer a variety of ways for you to get your prescription such as delivery, drive-thru, and walk-in pickup so there`s no frustrating long-lines to wait in. This will allow you to spend more time with your family, or return to your busy schedule of work or school! We offer compounding, which allows us to work with your physician to customized your prescription to your individual needs. We care for your love one`s well-being just as much as you do! Whether it`s your children, parents, or pets! We offer a variety of methods to make it easier for you to get them to comply with their medication
North Carolina Mutual Drug Company is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has four product candidates in development. LJPC-501 is La Jolla’s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension and hepatorenal syndrome. GCS-100 is La Jolla’s first-in-class galectin-3 inhibitor for the potential treatment of chronic kidney disease. LJPC-1010, La Jolla’s second-generation galectin-3 inhibitor, is a more potent and purified derivative of GCS-100 that can be delivered orally for the potential treatment of nonalcoholic steatohepatitis and other diseases characterized by tissue fibrosis. LJPC-401 is La Jolla’s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hemochromatosis and beta thalassemia